The β-hexosaminidase deficiency disorders: Development of a clinical paradigm in the mouse

Annals of Medicine

Volumn 29, Issue 6, 1997, Pages 557-561

  Tifft, Cynthia J ^a   Proia, Richard L ^b,c  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Animal models; G(M2) gangliosidosis; Lysosomal storage diseases; Mucopolysaccharidosis; Sandhoff disease; Tay Sachs disease

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE; BETA N ACETYLHEXOSAMINIDASE A; GANGLIOSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME DEFICIENCY; GANGLIOSIDOSIS; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; SANDHOFF DISEASE; STEM CELL; TAY SACHS DISEASE;

EID: 0031426040     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899709007482     Document Type: Conference Paper

References (16)

1. 2 gangliosidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease, 6th edn. New York: McGraw-Hill, 1989: 1807-39.
2. 2 gangliosidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease, 7th edn. New York: McGraw-Hill, 1995: 2839-79.
3. Conzelmann E, Sandhoff K. Biochemical basis of late-onset neurolipidoses. Dev Neurosci 1991; 13: 197-204.
4. Leinekugel P, Michel S, Conzelmann E, Sandhoff K. Quantitative correlation between the residual activity of β-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum Genet 1992; 88: 513-23.
5. Federico A, Palmeri S, Malandrini A, Fabrizi G, Guazzi GC. The clinical aspects of adult hexosaminidase deficiencies. Dev Neurosci 1991; 13: 280-7.
6. Adachi M, Schneck L, Volk BW. Ultrastructural studies of eight cases of fetal Tay-Sachs disease. Lab Invest 1974; 30: 102-12.
7. Suzuki K. Neuropathology of late onset gangliosidoses. Dev Neurosci 1991; 13: 205-10.
8. Capecchi MR. Altering the genome by homologous recombination. Science 1989; 244: 1288-92.
9. Koller BH, Smithies O. Altering genes in animals by gene targeting. Annu Rev Immunol 1992; 10: 705-30.
10. Yamanaka S, Johnson MD, Grinberg A, et al. Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease. Proc Natl Acad Sci USA 1994; 91: 9975-9.
11. Sango K, Yamanaka S, Hoffmann A, et al. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat Genet 1995; 11: 170-6.
12. Sango K, McDonald MP, Crawley JN, et al. Mice lacking both subunits of lysosomal β-hexosaminidase exhibit mucopolysaccharidosis and gangliosidosis. Nat Genet 1996; 14: 348-52.
13. Taniike M, Yamanaka S, Proia RL, Langaman C, Bone-Turentine T, Suzuki K. Neuropathology of mice with targeted disruption of Hexa gene, a model of Tay-Sachs disease. Acta Neuropathol 1995; 89: 296-304.
14. Navon R, Padeh B, Adam A. Apparent deficiency of hexosaminidase A in healthy members of a family with Tay-Sachs disease. Am J Hum Genet 1973; 25: 287-93.
15. M2 gangliosidosis, the adult form of Tay-Sachs disease. Science 1989; 243: 1471-4.
16. Suzuki K, Sango K, Proia RL, Langaman C. Mice deficient in all forms of lysosomal β-hexosaminidase show mucopolysaccharidosis-like pathology. J Neuropathol Exp Neurol 1997; 56: 693-703.